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ExtEndEd rEport
MR-PheWAS: exploring the causal effect of SUA 
level on multiple disease outcomes by using genetic 
instruments in UK Biobank
xue Li,1 xiangrui Meng,1 Athina Spiliopoulou,2 Maria timofeeva,3 Wei-Qi Wei,4 
Aliya Gifford,4 xia Shen,1,5 Yazhou He,1,6 tim Varley,7 paul McKeigue,2 
Ioanna tzoulaki,8,9,10 Alan F Wright,11 peter Joshi,1 Joshua C denny,4 Harry Campbell,1 
Evropi theodoratou1,12
AbstrACt
Objectives We aimed to investigate the role of serum 
uric acid (SUA) level in a broad spectrum of disease 
outcomes using data for 120 091 individuals from UK 
Biobank.
Methods We performed a phenome-wide association 
study (pheWAS) to identify disease outcomes associated 
with SUA genetic risk loci. We then implemented 
conventional Mendelian randomisation (Mr) analysis 
to investigate the causal relevance between SUA level 
and disease outcomes identified from pheWAS. We 
next applied Mr Egger analysis to detect and account 
for potential pleiotropy, which conventional Mr 
analysis might mistake for causality, and used the HEIdI 
(heterogeneity in dependent instruments) test to remove 
cross-phenotype associations that were likely due to 
genetic linkage.
results our pheWAS identified 25 disease groups/
outcomes associated with SUA genetic risk loci 
after multiple testing correction (p<8.57e-05). our 
conventional Mr analysis implicated a causal role 
of SUA level in three disease groups: inflammatory 
polyarthropathies (or=1.22, 95% CI 1.11 to 1.34), 
hypertensive disease (or=1.08, 95% CI 1.03 to 1.14) 
and disorders of metabolism (or=1.07, 95% CI 1.01 
to 1.14); and four disease outcomes: gout (or=4.88, 
95% CI 3.91 to 6.09), essential hypertension (or=1.08, 
95% CI 1.03 to 1.14), myocardial infarction (or=1.16, 
95% CI 1.03 to 1.30) and coeliac disease (or=1.41, 
95% CI 1.05 to 1.89). After balancing pleiotropic effects 
in Mr Egger analysis, only gout and its encompassing 
disease group of inflammatory polyarthropathies were 
considered to be causally associated with SUA level. our 
analysis highlighted a locus (ATXN2/S2HB3) that may 
influence SUA level and multiple cardiovascular and 
autoimmune diseases via pleiotropy.
Conclusions Elevated SUA level is convincing to cause 
gout and inflammatory polyarthropathies, and might act 
as a marker for the wider range of diseases with which 
it associates. our findings support further investigation 
on the clinical relevance of SUA level with cardiovascular, 
metabolic, autoimmune and respiratory diseases.
IntrOduCtIOn
Uric acid (UA) is the end product of the exoge-
nous and endogenous purine metabolism, cata-
lysed by the action of xanthine oxidase.1 Due 
to the evolved loss of uricase enzyme, humans 
are unable to convert UA into highly soluble 
compounds, leaving urate circulating in the blood 
and resulting in a high basal level of serum uric 
acid (SUA).2 The prevalence rate of hyperuri-
caemia (elevated SUA level >7.0 mg/dL) is in the 
range of 5%–25% across different countries.3–5 A 
progressively rising trend of hyperuricaemia prev-
alence has been observed worldwide.5 Concern-
edly, hyperuricaemia is thought to inflict multiple 
clinical consequences, which is believed to be 
causally related to gout and suggestively associ-
ated with a number of prevalent health conditions, 
such as cardiovascular and metabolic diseases.6–8 
Our recently published umbrella review 
presented a comprehensive overview of the 
breadth of disease outcomes related to SUA 
level by incorporating evidence from multiple 
sources.9 A large number of disease outcomes 
were reported to be associated with SUA level in 
observational studies, covering a wide range of 
diseases, including cardiovascular disease, meta-
bolic syndrome, diabetes, cancer and neurological 
disorders. However, evidence as to whether these 
associations are actually causal is not yet well 
developed, given that observational associations 
are susceptible to a variety of biases, confounding 
and/or reverse causality. Although results from 
randomised controlled trials (RCTs) have provided 
some evidence about the beneficial effects of 
SUA-lowering therapy on some intermediate traits 
or biomarkers (eg, blood pressure, endothelial 
function, serum creatinine), there remains a lack 
of RCTs focusing on the more important clinical 
disease endpoints.10–12 A number of Mendelian 
randomisation (MR) studies, using the genetic 
variants influencing SUA level as instruments, 
provide alternative evidence to distinguish causal 
from non-causal associations. However, these MR 
studies examined a limited set of disease outcomes 
and were not able to detect moderate effect size 
due to limited power.13–19 Increasing sample size 
and the range of outcomes in an enlarged MR 
study thus offers the prospect of deeper and wider 
insight into the causal role of SUA.
MR analysis is typically hypothesis-driven based 
on prior knowledge to specify the outcome to be 
examined in relation to the exposure of interest. 
Traditionally, only one (or a limited number) 
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association between the exposure and one (or a few) predefined 
outcome(s) is tested in an MR study. Recently, phenome-wide 
Mendelian randomisation (MR-PheWAS) analysis has been 
proposed by integrating the phenome-wide association study 
(PheWAS) and MR method to build a hypothesis-searching 
approach, which aims to explore potential causal relationships 
between an exposure (using genetic instruments as proxies) 
and a range of phenome-wide disease outcomes in a high-
throughput manner.20 This approach is effective in evalu-
ating or replicating the associations reported in observational 
studies, as well as discovering new relationships and gener-
ating new hypotheses on the genetic architecture shared by the 
related phenotypes. With its wealth of genotypic and pheno-
typic data collected in very large numbers, the UK Biobank 
study provides an excellent opportunity to explore the causal 
role of SUA level across a broad spectrum of disease outcomes. 
In this study, we performed an MR-PheWAS in UK Biobank 
database to discover disease outcomes related to genetic varia-
tions of SUA level and to investigate if any association is causal.
MetHOds
uK biobank data
The UK Biobank is a large-scale, population-based, prospective 
cohort that enrolled over 500 000 participants aged 40–69 years. 
The recruited participants provided a wide range of self-re-
ported baseline information. Blood samples were collected for 
biochemical tests and genotyping. Their national health records 
have been linked with the baseline and genotypic data for longi-
tudinal follow-up. Genotypic and phenotypic data used in this 
study were obtained from UK Biobank under an approved data 
request application (application ID: 10775).
Genotyping and quality control
Genotyping, quality control and genetic imputation were 
performed by the UK Biobank team prior to the interim release 
of genotypic data for 150 000 participants. The procedure of 
genotyping and quality control is presented in detail at https:// 
biobank. ctsu. ox. ac. uk/ crystal/ docs/ genotyping_ qc. pdf. We used 
the field variables made available by the UK Biobank for quality 
control to exclude the samples that had high missingness or 
heterozygosity, outlying short runs of homozygosity, and sex 
mismatch (see online supplementary table S1). We constrained 
our analyses to participants who were self-reported British 
and confirmed to be Caucasians based on the genetic principal 
component analysis performed by the UK Biobank. The quality 
control process generated a genotypic data set output with 
120 091 individuals included in the current analysis.
Phenotyping and mapping ICd-10 or ICd-9 to phecode
We focused on phenotypes in relation to diagnostic disease 
outcomes. We analysed two phenotypic data sets (inpatient 
hospital episode records and cancer registry data) in the UK 
Biobank using the phecode schema (see online supplementary 
text for phenotyping and mapping process).21 The coding for 
clinical diagnoses in these data sets followed the WHO’s Interna-
tional Classification of Diseases (ICD) coding systems, but used 
different ICD versions (ICD-10 or ICD-9) according to the date 
of record. We included both ICD-10 and ICD-9 codes to define 
the case and control groups. Since cancer registry data over-
lapped with the cancer diagnosis in inpatient hospital records, 
we pooled the cancer registry data into the hospital episode data 
as a complement to the cancer diagnosis.
statistical analysis
The statistical analysis included three main steps: first, we 
performed a PheWAS to identify disease outcomes that were asso-
ciated with genetic risk loci of SUA level; second, we performed 
MR analysis by using both the inverse-variance weighted (IVW) 
method and MR Egger approach to explore causal relationship 
for identified PheWAS asscoations22 23; and third, we applied 
HEIDI (heterogeneity in dependent instruments) test to exclude 
the cross-phenotype associations caused by genetic linkage.24
Genetic instruments
We selected 31 SUA-associated single nucleotide polymor-
phisms (SNPs) as genetic instruments (see online supplementary 
table S2), which were previously reported to be independently 
associated with SUA level in genome-wide association studies 
(GWAS).25 26 We obtained the SNP effect on SUA level from 
the largest GWAS performed in European population.25 The 
overall proportion of variance (R2 of SUA level explained by 
the selected genetic instruments) was estimated to be close to 
7.0%.25
Phenome-wide association analysis
In phenome-wide analysis, we used 31 SUA-associated SNPs 
as genetic instruments individually to scan across a wide range 
of disease outcomes defined by the phecode system.21 With 
the PheWAS algorithm,27 a series of case–control tests was 
performed: (1) the case group was generated by including 
patients with the tested phecode; (2) participants were 
assigned to the control group based on the absence of both 
the tested phecode and related phecodes (patients who had 
the parent, child or sibling phecodes of the tested phecode 
were excluded from the control group)27; and (3) to ensure 
statistical power, analysis was only performed for phecode 
with no less than 200 cases. This minimum number of cases 
was suggested based on a simulation of power estimates for 
PheWAS analysis.28 We used logistic regression to test the asso-
ciations between 31 individual genetic instruments (assuming 
an additive genetic model) and each phecode (number of 
cases ≥200) after adjusting for multiple covariates, including 
sex, body mass index (BMI), age, assessment centre and the 
principal components. Considering many phecodes were not 
independent, we used the false discovery rate (FDR) method 
to account for multiple testing.29
MR IVW, MR Egger and HEIDI test
We then explored the identified PheWAS associations in three 
possible scenarios (see online supplementary figure S1): (1) 
causality: the observed association was causal (through the SUA 
pathway); (2) pleiotropy: the observed association was due to 
pleiotropic effect of one causal variant (ie, linked to SUA level 
and the particular disease outcome through pleiotropy); and (3) 
genetic linkage: the observed association was caused by the 
linkage disequilibrium (LD) between two distinct causal variants, 
with one affecting SUA level and the other affecting the disease 
outcome.
MR IVW
To explore if there was any causal effect on identified disease 
outcomes, we performed the conventional MR analysis by 
pooling the individual effect of each SNP using the IVW method 
to estimate the overall causal effect (see online supplementary 
text).30
group.bmj.com on March 1, 2018 - Published by http://ard.bmj.com/Downloaded from 
3Li X, et al. Ann Rheum Dis 2018;0:1–9. doi:10.1136/annrheumdis-2017-212534
Clinical and epidemiological research
MR Egger
We then performed MR Egger to attempt to correct for any 
potential pleiotropic effect in the causal estimates. This approach 
is applied to balance the pleiotropic effects derived from multiple 
genetic instruments (see online supplementary text).23
HEIDI test
We calculated HEIDI statistics for the SUA genetic loci that were 
associated with more than one disease outcome. This test was to 
examine if the cross-phenotype association was due to genetic 
linkage (see online supplementary text).24
sex stratification analysis
To account for any sex difference, we performed PheWAS and 
MR analyses in men and women separately. The sex-specific 
effects of SNPs on SUA level (see online supplementary table 
S2) were taken from the summary-level GWAS data provided by 
Köttgen et al.25
results
A total of 120 091 UK Biobank participants were included in 
the analysis, consisting of 56 845 men and 63 246 women with a 
mean age of 64.86 years in 2016 (SD of 7.95) (see online supple-
mentary table S3). Within phenotypic data sets, we identified 
684 324 hospital episodes and 23 174 cancer registration records, 
which included 7990 unique ICD-10 codes and 1998 unique 
ICD-9 codes. After mapping diagnostic ICD-10 or ICD-9 codes 
to phecodes, the phenotypic data consisted of 1807 distinct 
phecodes. After filtering out disease outcomes with low prev-
alence (number of cases <200), 568 phecodes (median number 
of cases=694 (range: 200–39 142)) were included in PheWAS 
analysis. These 568 phecodes were classified into 17 broadly 
related disease categories (table 1). We noted that the distribu-
tion of phenotypes examined was skewed across the different 
disease categories (see online supplementary figure S2), in which 
a large number of disease phenotypes were included in digestive, 
circulatory, endocrine and metabolic systems, but some disease 
categories, for example congenital anomalies, were not well 
represented in the study population.
Phenome-wide association analysis
The PheWAS analysis performed 17 608 case–control tests, 
leading  to  an  adjusted  significance  threshold  of  P<8.57e-05 
corresponding to an FDR of q<0.05 to account for the multiple 
testing. A total of 27 pairs of genotype–phenotype associations 
passed the significance threshold of FDR correction (P<8.57e-
05) in the overall PheWAS analysis with adjustment for covari-
ates (table 2). Results of PheWAS without adjustment for BMI 
are shown in online supplementary table S4. The sex-stratified 
PheWAS analysis identified 10 pairs of genotype–phenotype 
association in men and 10 pairs of genotype–phenotype asso-
ciation in women (see online supplementary table S5). When 
compared with the overall PheWAS analysis, five new pairs of 
association were identified from the sex-stratified PheWAS anal-
ysis (see online supplementary table S5).
These identified genotype–phenotype associations were distrib-
uted across 15 SUA genetic loci, of which 5 loci were associated 
with more than one disease outcome: rs653178 in ATXN2/SH2B3 
locus (number of disease outcomes: noutcomes = 10), rs1165151 
in SLC17A3 locus (noutcomes = 3), rs1260326 in GCKR locus 
(noutcomes = 3), rs2231142 in ABCG2 locus (noutcomes = 4) and 
rs2079742 in BCAS3 locus (noutcomes = 2). Of note, six disease 
outcomes shared genetic associations with SUA level at more than 
one locus: gout (number of loci: nloci = 3), inflammatory poly-
arthropathies (nloci = 2), disorders of iron metabolism (nloci = 2
), coeliac disease (nloci = 2), hypertensive disease (nloci = 2) and 
essential hypertension (nloci = 2).
In summary, the PheWAS analyses identified 25 unique 
disease groups/outcomes (corresponding to 25 unique phecodes) 
that shared genetic risk loci with SUA level, which included 9 
disease groups (inflammatory polyarthropathies, hypertensive 
disease, circulatory disease, disorders of metabolism, disorders 
of thyroid, other diseases of respiratory system, disorder of skin 
and subcutaneous tissue, benign neoplasm of digestive system, 
and complications of labour and delivery) and 16 specific disease 
outcomes (gout, essential hypertension, angina pectoris, myocar-
dial infraction, coronary atherosclerosis, ischaemic heart disease, 
atrial fibrillation and flutter, varicose veins of lower extremity, 
hypercholesterolaemia, disorders of iron metabolism, coeliac 
table 1 The number of phenotypes and the number of cases in each disease category
disease categories Phenotypes (n)
Cases (n)
Minimum Median Mean Maximum
Circulatory system 61 221 665 2937 39 142
Congenital anomalies 6 206 265 302 522
Dermatological diseases 24 201 706 2736 32 738
Diseases in sense organs 34 201 425 1216 11 306
Digestive diseases 73 201 949 2176 23 129
Neoplasms 59 203 763 1916 30 101
Infectious diseases 16 205 787 975 3192
Endocrine and metabolic diseases 25 229 492 2304 13 592
Haematopoietic diseases 10 205 1187 1600 3669
Neurological diseases 21 229 452 1282 11 828
Respiratory diseases 38 219 712 1713 19 238
Mental disorders 18 205 673 1926 8942
Genitourinary diseases 77 200 666 1606 29 859
Pregnancy complications 11 227 360 707 2531
Musculoskeletal diseases 44 263 1076 2482 21 822
Clinical symptoms 14 267 1237 2570 12 287
Injuries and poisonings 37 211 589 911 4842
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disease, hypothyroidism, gastritis and duodenitis, poisoning by 
antibiotics, cataract, and nasal polyps). The mappings of ICD 
codes to these 25 phecodes and their hierarchical relationships 
are shown in online supplementary table S6.
Mr IVW, Mr egger and HeIdI test
We then performed MR analysis using the IVW method to 
explore if there was any causal link between SUA level and the 25 
disease groups/outcomes identified from PheWAS analysis. The 
MR IVW analysis suggested a potential causal link for 7 out of 
25 disease groups/outcomes. The corresponding effect estimate 
on each disease outcome is presented in table 3. It was indicated 
that genetically determined higher SUA level was potentially 
causally linked with an increased risk of three disease groups, 
including inflammatory polyarthropathies (OR=1.22, 95% CI 
1.11 to 1.34, P=1.10e-04), hypertensive disease (OR=1.08, 
95% CI 1.03 to 1.14, P=0.004) and disorders of metabolism 
(OR=1.07, 95% CI 1.01 to 1.14, P=0.03), and of four specific 
disease outcomes, including gout (OR=4.88, 95% CI 3.91 to 
6.09, P=3.55e-15), essential hypertension (OR=1.08, 95% CI 
1.03 to 1.14, P=0.005), myocardial infarction (OR=1.16, 
95% CI 1.03 to 1.30, P=0.015) and coeliac disease (OR=1.41, 
95% CI 1.05 to 1.89, P=0.02).
To explore and correct for any possible pleiotropic effect of 
multiple instruments, we then conducted the MR Egger analysis 
(table 3). After balancing out the potential pleiotropic effects, 
the putative causal link of SUA level with gout (OR=4.58, 
95% CI 2.72 to 7.72, Peffect= 1.76e-06) and its umbrella disease 
group, inflammatory polyarthropathies (OR=1.15, 95% CI 1.01 
to 1.31, Peffect=0.03), remained statistically significant and there 
was no indication of unbalanced pleiotropy (Ppleiotropy=0.73 and 
Ppleiotropy=0.23, respectively). The putative causal effect of SUA 
level on the other five disease groups/outcomes was not statis-
tically significant in the MR Egger model. The causal effects of 
each individual SNPs on these seven disease groups/outcomes 
are shown in online supplementary figures S3–S9. Unbalanced 
pleiotropy was observed for essential hypertension (Ppleiotropy
=0.001) and its umbrella disease group, hypertensive disease 
(Ppleiotropy=0.001). For myocardial infarction, coeliac disease 
and disorders of metabolism, the putative causal effect was not 
statistically significant in the MR Egger model (Peffect=0.75, 
Peffect =0.41 and Peffect=0.80, respectively), although there 
was no evidence of unbalanced pleiotropy (Ppleiotropy=0.13, 
Ppleiotropy =0.75 and Ppleiotropy=0.18, respectively). The results 
of the sex-stratified MR IVW are presented in online supple-
mentary table S7.
Finally, to distinguish the genotype–phenotype association 
of pleiotropy from LD, the HEIDI test was performed for the 
five genetic loci (rs653178 in ATXN2/SH2B3 locus, rs1165151 
in SLC17A3 locus, rs1260326 in GCKR locus, rs2231142 in 
ABCG2 locus and rs2079742 in BCAS3 locus) that were associ-
ated with multiple disease outcomes in the PheWAS analysis (see 
online supplementary figures S10–S14). Based on the HEIDI 
table 2 Genotype–phenotype associations identified from PheWAS after correcting multiple testing by FDR (P<8.57e-05)
Phecode description snP_risk allele*
Allele 
frequency total (n) Cases (n) Or (95% CI) P†
274.1 Gout rs2231142_T 0.11 119 555 1003 1.89 (1.69 to 2.12) 5.41e-28
275.1 Disorders of iron metabolism rs1165151_G 0.45 119 063 205 3.56 (2.78 to 4.56) 1.41e-23
244.4 Hypothyroidism rs653178_C 0.48 118 821 4146 1.21 (1.16 to 1.27) 3.90e-17
246 Disorders of thyroid rs653178_C 0.48 119 601 4926 1.18 (1.14 to 1.23) 8.82e-16
274.1 Gout rs12498742_A 0.23 118 960 1002 1.54 (1.37 to 1.74) 7.94e-13
275.1 Disorders of iron metabolism rs742132_A 0.29 119 271 205 2.80 (2.10 to 3.74) 3.13e-12
401 Hypertensive disease rs653178_C 0.48 119 762 23 634 1.06 (1.04 to 1.09) 1.68e-08
401.1 Essential hypertension rs653178_C 0.48 119 688 23 560 1.06 (1.04 to 1.09) 2.00e-08
411.4 Coronary atherosclerosis rs653178_C 0.48 119 460 9526 1.09 (1.05 to 1.12) 1.27e-07
411 Ischaemic heart disease rs653178_C 0.48 119 401 9467 1.09 (1.05 to 1.12) 1.33e-07
211 Benign neoplasm of digestive system rs11264341_C 0.43 117 030 1504 0.83 (0.77 to 0.89) 2.41e-07
274.1 Gout rs1260326_T 0.39 119 555 1003 1.26 (1.15 to 1.38) 3.86e-07
459.9 Circulatory disease rs653178_C 0.48 119 677 39 142 1.05 (1.03 to 1.06) 2.24e-06
411.2 Myocardial infarction rs653178_C 0.48 113 559 3625 1.12 (1.07 to 1.18) 2.80e-06
557.1 Coeliac disease rs1165151_G 0.45 99 783 549 1.33 (1.18 to 1.51) 4.30e-06
557.1 Coeliac disease rs653178_C 0.48 99 965 550 1.31 (1.16 to 1.48) 9.28e-06
427.2 Atrial fibrillation and flutter rs6598541_A 0.35 113 261 4333 1.11 (1.06 to 1.16) 9.92e-06
960 Poisoning by antibiotics rs1165151_G 0.45 112 343 1027 0.82 (0.75 to 0.90) 1.22e-05
535 Gastritis and duodenitis rs478607_G 0.15 115 386 5233 1.12 (1.07 to 1.19) 1.34e-05
411.3 Angina pectoris rs653178_C 0.48 114 967 5033 1.09 (1.05 to 1.14) 3.01e-05
669 Complications of labour and delivery rs729761_G 0.28 113 240 2376 1.17 (1.09 to 1.26) 3.78e-05
272.11 Hypercholesterolaemia rs1260326_T 0.39 118 921 10 201 1.07 (1.03 to 1.10) 3.82e-05
366 Cataract rs6770152_G 0.43 116 218 4567 1.09 (1.05 to 1.14) 4.14e-05
471 Nasal polyps rs10821905_A 0.17 112 745 983 1.26 (1.13 to 1.40) 4.61e-05
454.1 Varicose veins of lower extremity rs2231142_T 0.11 111 390 3204 0.84 (0.78 to 0.92) 5.79e-05
401 Hypertensive disease rs2079742_T 0.13 115 659 22 832 1.07 (1.03 to 1.10) 7.00e-05
401.1 Essential hypertension rs2079742_T 0.13 115 588 22 761 1.07 (1.03 to 1.10) 7.02e-05
*Effect allele was harmonised to be the SUA-raising allele defined by Köttgen et al.25
†Significance threshold of P<8.57e-05 corresponds to an FDR of q<0.05 after correcting the multiple testing.
FDR, false discovery rate; PheWAS, phenome-wide association study; SUA, serum uric acid. 
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test, we identified 14 disease outcomes that were associated with 
the SUA genetic risk loci due to pleiotropy (with PHEIDI  >0.05). 
The strongest pleiotropic locus was the ATXN2/SH2B3, where 
three SNPs (rs653178, rs4766578 and rs3184504) in near-com-
plete LD (r2=0.99) were tagged as the lead SNPs associated 
with 10 disease groups/outcomes as a cluster of cardiovascular 
diseases and autoimmune disorders (see online supplementary 
figure S10). Other potential pleiotropic effects included the asso-
ciations of BCAS3 locus (rs2079742) with essential hypertension 
(PHEIDI=0.10) and hypertensive disease (PHEIDI=0.09) (see 
online supplementary figure S11), the associations of ABCG2 
locus (rs2231142) with varicose veins of lower extremity 
(PHEIDI=0.32) (see online supplementary figure S12), and the 
association of SLC17A3 locus (rs1165151) with poisoning by 
antibiotics (PHEIDI=0.26) (see online supplementary figure 
S13).
Our  analysis  rejected  the  null  hypothesis  of  a  pleiotropic 
model for the shared genetic association between SUA level and 
disorders of iron metabolism at the SLC17A3 locus (rs1165151) 
(PHEIDI=5.54e-28); we identified a different causal variant 
(rs17342717 in SLC17A1) that was in LD with the SNP 
rs1165151 (r2=0.24) and strongly associated with the disorders 
of iron metabolism (P=1.69e-129) (see online supplementary 
figure S13). Similarly, for the associations between the SLC17A3 
locus (rs1165151) and coeliac disease (PHEIDI=6.51e-16) 
(see online supplementary figure S13), and the GCKR locus 
(rs1260326) and hypercholesterolaemia (PHEIDI=3.27e-11) 
(see online supplementary figure S14), the pattern of shared 
regional genetic association was more consistent with a genetic 
linkage model, and the SNP with the smallest P value was tagged 
as an index of the distinct causal variant affecting the examined 
disease outcome.
dIsCussIOn
In PheWAS analysis by using SUA-associated SNPs as genetic instru-
ments, we replicated the findings of the largest GWAS performed 
by Köttgen and the findings of the most recent candidate gene-
based association study conducted in UK Biobank, which indi-
cated that two SUA-related SNPs (rs12498742 in SLC2A9 locus 
and rs2231142 in ABCG2 locus) are significantly associated with 
gout at GWAS P value threshold (P<5.0e-08).25 31 We conducted 
a conventional MR analysis (using the IVW method) and an MR 
Egger analysis, which accounts for potential pleiotropic effects, 
to investigate potential causal links with SUA level. These both 
confirmed potential causal effects of SUA level on gout and 
inflammatory polyarthropathies. The latter category represents 
the disease group term that includes gout, and thus this finding 
may  just  reflect  the  causal  role  of  SUA  in  gout. However,  this 
study cannot exclude a causal association between SUA and other 
inflammatory polyarthropathies, and this may be worth further 
study. Given that many comorbidities are commonly reported in 
patients with gout, it is of interest to consider the evidence for 
SUA sharing genetic risk loci with some of these diseases, such as 
cardiovascular/metabolic diseases and autoimmune disorders, and 
the evidence for a possible causal role for SUA in these conditions.
table 3 PheWAS associations assessed by conventional MR IVW and MR Egger analysis
disease outcomes
Mr IVW Mr egger
Or (95% CI) P effect Power* Or (95% CI) P effect P pleiotropy Power*
Gout 4.88 (3.91 to 6.09) 3.55e-15 1.00 4.58 (2.72 to 7.72) 1.76e-06 0.73 1.00
Inflammatory polyarthropathies† 1.22 (1.11 to 1.34) 1.10e-04 0.99 1.15 (1.01 to 1.31) 0.03 0.23 0.83
Essential hypertension 1.08 (1.03 to 1.14) 5.07e-03 0.82 0.93 (0.83 to 1.05) 0.23 1.13e-03 0.73
Hypertensive disease 1.08 (1.03 to 1.14) 4.23e-03 0.82 0.93 (0.83 to 1.05) 0.24 1.19e-03 0.73
Myocardial infarction 1.16 (1.03 to 1.30) 0.02 0.70 1.03 (0.84 to 1.27) 0.75 0.13 0.08
Coeliac disease 1.41 (1.05 to 1.89) 0.02 0.72 1.31 (0.68 to 2.54) 0.41 0.75 0.48
Disorders of metabolism† 1.07 (1.01 to 1.14) 0.03 0.52 1.01 (0.91 to 1.14) 0.80 0.18 0.06
Coronary atherosclerosis 1.07 (0.99 to 1.15) 0.08 0.41 0.99 (0.85 to 1.17) 0.95 0.20 0.06
Ischaemic heart disease 1.07 (0.99 to 1.15) 0.09 0.41 0.99 (0.85 to 1.16) 0.91 0.20 0.06
Angina pectoris 1.04 (0.94 to 1.15) 0.41 0.11 0.95 (0.80 to 1.12) 0.51 0.11 0.15
Atrial fibrillation and flutter 1.01 (0.91 to 1.12) 0.87 0.05 0.90 (0.75 to 1.08) 0.23 0.07 0.41
Circulatory disease 1.04 (1.00 to 1.09) 0.08 0.40 0.97 (0.89 to 1.07) 0.57 0.05 0.26
Varicose veins of lower extremity 0.86 (0.72 to 1.02) 0.09 0.55 0.86 (0.67 to 1.10) 0.24 0.97 0.55
Disorders of iron metabolism 1.19 (0.74 to 1.90) 0.45 0.11 0.79 (0.15 to 4.07) 0.77 0.47 0.12
Hypercholesterolaemia 1.14 (0.96 to 1.36) 0.12 0.94 1.18 (0.88 to 1.58) 0.27 0.78 0.99
Hypothyroidism 1.10 (0.99 to 1.23) 0.07 0.39 0.99 (0.75 to 1.32) 0.97 0.30 0.05
Disorders of thyroid 1.08 (0.98 to 1.20) 0.10 0.31 1.01 (0.79 to 1.29) 0.94 0.41 0.05
Benign neoplasm of digestive system 0.93 (0.78 to 1.10) 0.36 0.11 0.90 (0.64 to 1.26) 0.52 0.79 0.18
Gastritis and duodenitis 0.97 (0.88 to 1.07) 0.53 0.09 0.95 (0.80 to 1.13) 0.55 0.70 0.16
Nasal polyps 1.08 (0.88 to 1.34) 0.45 0.10 1.09 (0.73 to 1.60) 0.67 0.98 0.12
Cataract 0.99 (0.90 to 1.09) 0.85 0.05 0.91 (0.75 to 1.10) 0.34 0.23 0.36
Poisoning by antibiotics 0.85 (0.70 to 1.04) 0.14 0.25 1.00 (0.68 to 1.48) 1.00 0.28 0.05
Complications of labour and delivery† 0.89 (0.76 to 1.03) 0.12 0.30 0.78 (0.59 to 1.02) 0.08 0.20 0.83
Other diseases of respiratory system† 1.11 (0.94 to 1.31) 0.19 0.22 1.16 (0.92 to 1.46) 0.22 0.64 0.42
Disorder of skin and subcutaneous tissue† 0.99 (0.93 to 1.06) 0.77 0.06 0.98 (0.89 to 1.09) 0.75 0.85 0.09
*The statistical power of MR analyses was calculated by using the non-centrality parameter-based approach65; the overall proportion of variance (R2) of serum uric acid level 
explained by the genetic instruments was estimated to be 7.0%.25
†Disease outcomes identified from sex-stratified PheWAS analysis.
IVW, inverse-variance weighted; MR, Mendelian randomisation; PheWAS, phenome-wide association study. 
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Overall, we identified 32 pairs of genotype–phenotype asso-
ciations, which covered a wide range of phenotypic categories 
including endocrine/metabolic diseases, cardiovascular diseases 
and autoimmune disorders. Our PheWAS analysis replicated 
14 pairs of previously known genotype–phenotype (or closely 
related phenotypic groups) associations reported in the GWAS 
Catalog (see online supplementary table S2 and table 2). For 
example, rs653178 (ATXN2/SH2B3 locus) was previously 
reported to be associated with diastolic blood pressure,32 
myocardial infarction,33 peripheral artery disease,34 coeliac 
disease35 and serum thyroid peroxidase antibody levels.36 In our 
PheWAS, this SNP was statistically significantly associated with 
the same phenotypes (ie, coeliac disease, myocardial infarction) 
or similar phenotypic groups (ie, hypertension, circulatory and 
heart diseases, hypothyroidism and other disorders of thyroid). 
We also identified 18 novel genotype–phenotype associations (at 
the PheWAS threshold of P<8.57e-05), of which the associa-
tion between rs1165151 (SLC17A3 locus) and disorders of iron 
metabolism had the smallest P value (P=1.23e-19).
We performed conventional MR analysis, using the IVW 
method, to investigate whether there was a potential causal link 
between SUA level and the 25 unique disease groups/outcomes 
identified from PheWAS. The results of MR IVW analysis 
suggested a potential causal effect of SUA level on three disease 
groups, including inflammatory polyarthropathies (as noted 
above), hypertensive disease and disorders of metabolism, and 
four specific individual disease outcomes, including gout (as 
noted above), essential hypertension, myocardial infarction and 
coeliac disease. When adopting the advanced MR Egger anal-
ysis to account for potential pleiotropic effects, it is indicated 
that, except for gout and inflammatory polyarthropathies, all the 
other putative causal associations suggested by MR IVW analysis 
were probably inflated by the presence of pleiotropy. However, 
although the MR Egger analysis is more robust in dealing with 
pleiotropy, this method is not infallible.37 Intuitively, the genetic 
instrument with larger effect on SUA level is expected to have a 
larger effect on disease outcome and would exert stronger influ-
ence in the MR Egger regression model. With indepth exam-
ination of the individual SNP effects on SUA level against the 
SNP effects on disease outcomes (see online supplementary 
figures S5–S8), we found that the outlying variant (rs12498742 
in SLC2A9) that had the strongest association with SUA level 
showed a negative (null) effect on essential hypertension and 
hypertensive disease, which reversed the sign of the overall 
putative causal effect and led to a rejection of the intercept test. 
Given the influence of the outlying variant, the unbalanced plei-
otropy and relatively moderate statistical power (power=0.73), 
we would interpret that unbalanced pleiotropy between SUA 
level and hypertension is an issue for their causal inference in 
MR Egger analysis.
Previous observational studies have reported sex difference 
in the association between SUA level and the development of 
cardiovascular diseases,38–42 but few studies have addressed the 
sex difference by using MR approach to keep out the influence 
of environmental confounders. Our study identified a few more 
cardiovascular diseases (eg, coronary atherosclerosis, ischaemic 
heart disease) that were potentially causally linked with the 
genetic variation of SUA level in women, but not in men. These 
MR findings were concordant with results from observational 
studies, which indicated that the relationship between SUA level 
and cardiovascular disease was particularly strong in women, 
especially for heart disease.41 43 44 Although these putative causal 
associations specific to women were not verified by MR Egger, 
this may be due to the decreased statistical power of MR Egger 
(and a higher risk of type 2 error). The biological mechanism 
that can lead the association of SUA level with cardiovascular 
disease to be more pronounced in women than in men remains a 
matter for further investigation.
We also found that several PheWAS associations were likely 
driven by LD. For instance, the outstanding PheWAS association 
between disorders of iron metabolism and the SNP rs1165151 in 
SLC17A3 locus was not consistent with a pleiotropic model, and 
further examination found the SUA-associated SNP rs1165151 
was located in LD (r2=0.24), with the rs17342717 variant in 
SLC17A1 locus, which was strongly associated with disorders 
of iron metabolism (P=1.69e-129). This SNP (rs17342717) is 
also associated with red blood cell traits and serum iron levels 
in previous GWAS.45 46 We suggest that the implications of 
these findings have wider relevance for PheWAS studies. Typi-
cally, associations of a single SNP with multiple phenotypes 
were claimed to be due to pleiotropy in previous PheWAS.47 48 
However, as PheWAS focused on single variant without consid-
ering the correlations between SNPs, we would suggest that an 
additional examination of LD is necessary when we identify 
pleiotropic links.
In contrast, the pattern of shared regional genetic associa-
tions of SUA level with multiple disease outcomes at ATXN2/
S2HB3 locus was more consistent with a pleiotropic model, 
where we interpreted this locus influenced a cluster of cardiovas-
cular diseases and autoimmune disorders. However within the 
ATXN2/S2HB3 locus, there are three leading SNPs (rs653178, 
rs4766578 and rs3184504) in high LD (r2=0.99). In this case, 
we were unable to provide an indication of whether the observed 
associations are due to pleiotropy or genetic linkage, as it was 
difficult to infer the causal variant. Although SNP rs653178 
was reported as the lead variant influencing SUA level at this 
locus in GWAS, the potential biological mechanism underlying 
this effect is unclear.25 Furthermore, although the implication 
of the rs653178 on the regulation of blood pressure, cardiovas-
cular diseases and coeliac disease has been suggested by a few 
GWAS,32–35 a clear biological explanation for this role could not 
be demonstrated. Evidence from the functional follow-up of the 
S2HB3 gene indicated that rs3184504 may be the causal variant, 
as the S2HB3 gene encodes one of the S2HB family proteins, 
which have a diverse physiological roles on haematopoiesis, 
immune response and signalling, and variation in rs3184504 
may introduce a new phosphorylation site affecting the function 
of the S2HB protein.49 50 We believe that further uncovering of 
the biological functions of this pleiotropic locus (eg, gene func-
tion follow-up, expression quantitative trait loci analysis) might 
be helpful to understand the complex underlying relationship of 
SUA level with cardiovascular and autoimmune diseases.
The sex-stratified MR IVW analysis identified that unspecified 
diseases in respiratory system were potentially causally linked 
with SUA level in women (with the MR Egger analysis showing a 
consistent causal effect). This finding is consistent with recently 
published experimental studies, which demonstrated that human 
airway epithelial cells and lung tissue expressed a functional UA 
production/secretion system and UA was crucial in mediating 
the development of allergic airway diseases and regulating 
the antigen-specific T cell proliferation.51–54 It was also specu-
lated that fine, inhaled particulate matter can induce increased 
UA production in the human airway, which may contribute to 
allergic sensitisation and asthma pathogenesis.55 Evidence from 
other epidemiological studies suggested that high SUA level was 
associated with low lung function and high risk of respiratory 
symptoms and chronic obstructive pulmonary disease, but the 
direct causal relationship has not been established.56–58 Further 
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investigation may be worth to explore the clinical relevance of 
SUA level in lung health and respiratory diseases.
Key strengths of our study included its potential to make 
novel discoveries in genotype–phenotype associations and to 
identify novel cross-phenotype associations, possibly reflecting 
common aetiology or causal mechanisms. Unlike the genome, 
for which genetic structure can be measured by reliable biolog-
ical techniques, the definition of phenome varies across studies. 
Current published PheWAS have been limited primarily to 
billing ICD-9-clinical modification (CM) to phecode system, 
and the method for aggregating ICD-9-CM codes into phecodes 
has proven to be valuable in previous PheWAS studies.21 59 Our 
work broadened the utility of phecode system and illustrated 
the process of adopting phecode system in the updated ICD-10 
version to define the phenome framework. Our mapping process 
revealed some potential shortcomings of the current phecode 
system (eg, the ICD-10 codes involving the personal or family 
history were missing elements in the phecode system), which 
should be improved as a future undertaking. Recent method-
ological applications (eg, tree-structured phenotypic model 
(TreeWAS)) can be applied in future PheWAS analyses.60 As we 
were preparing the manuscript for submission, a web resource 
within UK Biobank, the GeneATLAS, was released in the bioRxiv 
(prior to peer review).61 We checked our PheWAS findings in this 
database, but only 10 of the 31 SUA-related SNPs were included 
in their database (and associations with some disease outcomes 
were replicated for these SNPs).61 We focused on the causal 
relationships between SUA level and binary disease outcomes in 
MR analyses, and these findings were complementary to MR 
estimates of urate archived in the MR-Base database (http:// eve. 
mrbase. org/), which mainly focused on quantitative traits.
On the other hand, our analysis was limited to phenotypes 
with no less than 200 cases; therefore, diseases with relatively 
low prevalence were not analysed. As the UK Biobank grows, 
we expect to perform PheWAS and MR analyses for more 
phenotypes, with the priority given to the ones of which the 
relationships with SUA level are much controversial, such as 
dementia.62 63 Furthermore for some analysed phenotypes, 
our PheWAS analysis may still have low power to detect small 
effect size. The use of the interim release of UK Biobank data 
and focusing on a very homogeneous population (self-reported 
British confirmed by principal component analysis (PCA)) 
limited the power of this study. Additionally, we did not analyse 
the self-reported UK Biobank data to avoid information bias, but 
this may have impacted on the comprehensiveness of PheWAS 
and have reduced the precision of MR estimates. To improve 
this limitation, we performed a sensitivity analysis for gout 
by comparing the MR estimates for hospital-diagnosed gout, 
self-reported gout and hospital-diagnosed/self-reported gout 
(see online supplementary table S8). The MR estimates were 
consistently statistically significant in any of the cases but with 
differences in their effect sizes. These differences might be due 
to the fact that gout cases ascertained from hospital discharge 
coding may be unrepresentative of gout, given hospitalised gout 
is more likely to be complicated by comorbidities, as reported 
by Robinson et al.64 While making efforts to dissect the PheWAS 
associations with different models, given the complexity of 
human genetic structure, these models are not mutually exclu-
sive and each model has its own methodological limitations, 
thus strong conclusions are not always possible. Therefore, the 
realistic goal for the present study was to assess different lines 
of evidence (ie, causality, pleiotropy or genetic linkage) in order 
to characterise the identified PheWAS associations in relation 
to SUA level. It would be beneficial to assess whether measured 
SUA level, rather than its genetic proxy, is also associated with 
the observed disease outcomes, but data on the SUA biomarker 
are not yet available in UK Biobank.
Overall, this PheWAS analysis demonstrated that SUA level 
shares genetic risk loci with multiple disease outcomes, partic-
ularly cardiovascular/metabolic diseases and autoimmune disor-
ders. These findings provide rationale for further investigation 
of whether these associations are causal. Our study indicated a 
putative causal effect of SUA level on three disease groups (inflam-
matory polyarthropathies, hypertensive disease and disorders of 
metabolism) and four specific disease outcomes (gout, essential 
hypertension, coeliac disease and myocardial infarction); when 
balancing out the pleiotropy, a robust conclusion about causality 
was made for gout and its encompassing disease group, inflam-
matory polyarthropathies. Unbalanced pleiotropy was identified 
as an issue for the causal inference on the association between 
SUA level and hypertension. Other potential causal relevance 
of SUA level with respiratory diseases is also worthy of further 
investigation. When interpreting the PheWAS associations from 
a view of pleiotropy, our analysis highlighted a key pleiotropic 
locus that influenced SUA level and multiple cardiovascular and 
autoimmune diseases. A further functional annotation of this 
locus might be helpful to understand the biological pathways 
that contribute to the phenotypic associations between SUA level 
and cardiovascular diseases (including hypertension).
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